Reteplase biosimilar - Shanghai Fudan-Zhangjiang/Shandong Ahua

Drug Profile

Reteplase biosimilar - Shanghai Fudan-Zhangjiang/Shandong Ahua

Alternative Names: r-tPA - Shanghai Fudan-Zhangjiang/Shandong Ahua; Recombinant tissue plasminogen activator derivative - Shanghai Fudan-Zhangjiang/Shandong Ahua; Rui Tong Li

Latest Information Update: 23 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Developer Shandong Ahua Biochemical
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top